We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-11.75%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$276M
AUM Growth
-$70.7M
Cap. Flow
-$1.52M
Cap. Flow %
-0.55%
Top 10 Hldgs %
87.96%
Holding
22
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$1.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
1
Arvinas
ARVN
$572M
$106M 38.37%
1,289,521
-18,666
-1% -$1.52M
HARP
2
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$23.8M 8.63%
315,670
– –
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.68B
$23.7M 8.6%
1,553,661
– –
RLYB icon
4
Rallybio
RLYB
$85.8M
$22M 7.96%
287,700
– –
PASG icon
5
Passage Bio
PASG
$14.1M
$15.9M 5.75%
124,896
– –
DICE
6
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$14.1M 5.1%
556,693
– –
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$11.8M 4.28%
1,209,571
– –
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$8.9M 3.23%
409,611
– –
APTX
9
DELISTED
Aptinyx Inc. Common Stock
APTX
$8.79M 3.18%
3,290,079
– –
CMRX
10
DELISTED
Chimerix, Inc.
CMRX
$7.87M 2.85%
1,224,600
– –
ALEC icon
11
Alector
ALEC
$198M
$7.01M 2.54%
339,569
– –
RCOR
12
DELISTED
Renovacor, Inc.
RCOR
$5.37M 1.95%
697,436
– –
AMYT
13
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$4.86M 1.76%
449,737
– –
COGT icon
14
Cogent Biosciences
COGT
$7.24B
$4.3M 1.56%
501,530
– –
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$8.92B
$4.01M 1.45%
141,000
– –
ARAV
16
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.07M 0.75%
946,423
– –
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$1.79M 0.65%
900,501
– –
TECX
18
Tectonic Therapeutic
TECX
$585M
$1.22M 0.44%
26,296
– –
PDSB icon
19
PDS Biotechnology
PDSB
$43.4M
$950K 0.34%
117,242
– –
XFOR icon
20
X4 Pharmaceuticals
XFOR
$438M
$767K 0.28%
11,167
– –
ITRM
21
DELISTED
Iterum Therapeutics
ITRM
$571K 0.21%
97,087
– –
ADXN
22
Addex Therapeutics
ADXN
$7.34M
$315K 0.11%
2,500
– –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q4 2021 Portfolio in Review

As of Q4 2021, New Leaf Venture Partners held 22 positions worth $276M, down 20% from $347M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Trading was light in Q4 2021: portfolio turnover was 0%. New Leaf Venture Partners opened no new positions and made no exits, leaving the 22-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • New Leaf Venture Partners's biggest Q4 2021 reduction was Arvinas, cutting an estimated $1.52M.
  • New Leaf Venture Partners's ten largest holdings make up 88% of its $276M portfolio in Q4 2021.
  • New Leaf Venture Partners opened 0 new positions and closed 0 in Q4 2021.
  • New Leaf Venture Partners's portfolio value fell 20% quarter-over-quarter to $276M.

Based on New Leaf Venture Partners's 13F filing for Q4 2021, filed 11 Feb 2022.